{'fraction_non_alphanumeric': 0.037178786221979225, 'fraction_numerical': 0.021323127392017496, 'mean_word_length': 5.1824324324324325, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hypokalemia in Hospitalized COVID-19 Patients: Prevalence and Correlates

Objectives: This study was designed to evaluate the prevalence, and the severity of hypokalemia, and the factors associated with hypokalemia among patients hospitalized with COVID-19. 
Methods: Random sampling technique was employed in this study. Socio-demographic data such as age, gender, weight (kg), height (meters) and BMI (kg/m2) as well as presenting symptoms (pulmonary and extra-pulmonary), duration of admission, the need for mechanical ventilation and treatment outcomes (discharged or died) as well as the plasma level of potassium (mmol/l) were extracted from the medical records of RT-PCR confirmed hospitalized cases of COVID-19 patients. Data collected were analyzed with IBM/ SPSS version 25.0 software. Discrete variables were presented as percentages and frequencies and the associations between qualitative variables tested using the Chi-square test at a level of significance of p < 0.05. 
Results: Hypokalaemia was detected in 61 out of 117 COVID-19 positive subjects used for this study during hospitalization. The mean serum potassium was 3.45±0.633 mmol/L. The majority of hypokalemic patients (n=35, 29.9%) patients experienced a mild decrease in serum potassium level (3–3.4 mmol/L). Risk factors for hypokalaemia were female sex and patients presenting with sneezing or/and sore throat. There was no relationship between the plasma potassium level and comorbid factors. There was no increasing trend of 30-day mortality associated with lower plasma potassium level. 
Conclusion: Plasma potassium levels should be monitored routinely and maintained within appropriate ranges in patients with COVID-19 especially in female patients as well as patient with significant upper respiratory symptoms such as sore throat and sneezing.